Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: July-08-10
Credit Expiration Date: July-31-12

Faculty

Michelle J. Lajiness, FNP-BC
Nurse Practitioner
Urology Associates
Beaumont Hospital
Royal Oak, MI

Credit Hours

1

Medium

Online Presentation

Program Description

THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING FEBRUARY 18, 2010. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.

Overactive bladder (OAB) is a chronic, debilitating condition that affects approximately 33 million Americans. The symptoms of OAB—urinary incontinence, urgency, and urinary frequency—often lead to further medical and psychological problems and can have a devastating impact on quality of life. However, many patients who suffer from OAB symptoms fail to tell their healthcare professionals about their problems.

While OAB is seen by primary care nurse practitioners (NPs) on a routine basis, NPs may not have the necessary tools, processes, and/or knowledge to readily evaluate patients for OAB symptoms. NPs who treat patients with OAB need to know how to effectively manage these conditions by utilizing nonpharmacologic and pharmacologic interventions appropriately.

Program Developer/Facilitator

Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education

Target Audience

This program was developed for nurse practitioners.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Implement measures to identify patients who "silently" suffer from OAB symptoms.
  2. Describe factors that contribute to untreated and undertreated OAB.
  3. Differentiate symptoms related to OAB from other voiding dysfunction conditions.
  4. Discuss the effectiveness, safety, and tolerability profiles of pharmacologic agents available for the treatment of OAB.
  5. Evaluate the role of combined behavioral therapy plus pharmacotherapy when treating patients who complain of OAB symptoms.

Disclosures

Ms Lajiness discloses that she has received consultant fees from Medtronic.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Credit Statements

This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1005157.



This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Commercial Support Statements


This activity is supported through an educational grant from Pfizer Inc.


This activity is supported through an educational grant from Astellas Pharma Global Development, Inc.


This activity is supported through an educational grant from Allergan, Inc.

Instructions

COMPLETING THE POST TEST AND EVALUATION:

  1. When you return to the AANP CE Center, login and find the program you wish to complete. On the program’s content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
  2. When you return to the AANP CE Center, login and find the program you wish to complete. On the program’s content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.

Certificate Fee

$0.00

Disclaimer

The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, Astellas Pharma Global Development, Inc., Allergan, Inc., or Pfizer Inc.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS